Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock went on an upward path that rose over 10.81% on Wednesday, amounting to a one-week price increase of more than 0.79%.
Over the last 12 months, ARQT stock rose by 71.49%. The one-year Arcutis Biotherapeutics Inc stock forecast points to a potential upside of 18.75. The average equity rating for ARQT stock is currently 1.25, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.97 billion, with 117.85 million shares outstanding and 104.39 million shares in the current float. Compared to the average trading volume of 2.33M shares, ARQT stock reached a trading volume of 5368318 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Arcutis Biotherapeutics Inc [ARQT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARQT shares is $20.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARQT stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Arcutis Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 30, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on August 28, 2024, representing the official price target for Arcutis Biotherapeutics Inc stock. Previously, the target price had yet another raise from $4 to $8, while Mizuho kept a Buy rating on ARQT stock. On October 26, 2023, analysts decreased their price target for ARQT shares from 57 to 4.
The Average True Range (ATR) for Arcutis Biotherapeutics Inc is set at 1.21, with the Price to Sales ratio for ARQT stock in the period of the last 12 months amounting to 10.02. The Price to Book ratio for the last quarter was 12.42, with the Price to Cash per share for the same quarter was set at 1.93.
ARQT Stock Performance Analysis:
Arcutis Biotherapeutics Inc [ARQT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.79. With this latest performance, ARQT shares gained by 23.88% in over the last four-week period, additionally plugging by 78.49% over the last 6 months – not to mention a rise of 71.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARQT stock in for the last two-week period is set at 58.53, with the RSI for the last a single of trading hit 58.86, and the three-weeks RSI is set at 57.96 for Arcutis Biotherapeutics Inc [ARQT]. The present Moving Average for the last 50 days of trading for this stock 14.16, while it was recorded at 15.81 for the last single week of trading, and 11.49 for the last 200 days.
Insight into Arcutis Biotherapeutics Inc Fundamentals:
Arcutis Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.97 and a Current Ratio set at 4.15.
Arcutis Biotherapeutics Inc [ARQT] Institutonal Ownership Details
There are presently around $112.09%, or 114.40%% of ARQT stock, in the hands of institutional investors. The top three institutional holders of ARQT stocks are: JENNISON ASSOCIATES LLC with ownership of 11.57 million shares, which is approximately 9.3712%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 10.0 million shares of the stock with an approximate value of $$93.04 million in ARQT stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$91.3 million in ARQT stock with ownership which is approximately 7.95%.
